These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 21151627)

  • 21. Risk of osteonecrosis of the jaw in cancer patients taking bisphosphonates.
    Gebara SN; Moubayed H
    Am J Health Syst Pharm; 2009 Sep; 66(17):1541-7. PubMed ID: 19710437
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Incidence of and risk for osteonecrosis of the jaw in Korean osteoporosis patients treated with bisphosphonates: A nationwide cohort-study.
    Kim SH; Lee YK; Kim TY; Ha YC; Jang S; Kim HY
    Bone; 2021 Feb; 143():115650. PubMed ID: 32956854
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intravenous bisphosphonate-related osteonecrosis of the jaw: bone scintigraphy as an early indicator.
    O'Ryan FS; Khoury S; Liao W; Han MM; Hui RL; Baer D; Martin D; Liberty D; Lo JC
    J Oral Maxillofac Surg; 2009 Jul; 67(7):1363-72. PubMed ID: 19531404
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Osteonecrosis of the jaw in patients on bisphosphonate treatment. review of literature with contribution of a case of multiple myeloma.
    Goranova-Marinova VS; Pechalova-Petrova PF; Goranov SG
    Folia Med (Plovdiv); 2009; 51(4):53-7. PubMed ID: 20232660
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate.
    Walter C; Al-Nawas B; Grötz KA; Thomas C; Thüroff JW; Zinser V; Gamm H; Beck J; Wagner W
    Eur Urol; 2008 Nov; 54(5):1066-72. PubMed ID: 18602738
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates.
    Hoff AO; Toth BB; Altundag K; Johnson MM; Warneke CL; Hu M; Nooka A; Sayegh G; Guarneri V; Desrouleaux K; Cui J; Adamus A; Gagel RF; Hortobagyi GN
    J Bone Miner Res; 2008 Jun; 23(6):826-36. PubMed ID: 18558816
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer.
    Guarneri V; Miles D; Robert N; Diéras V; Glaspy J; Smith I; Thomssen C; Biganzoli L; Taran T; Conte P
    Breast Cancer Res Treat; 2010 Jul; 122(1):181-8. PubMed ID: 20361252
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Bisphosphonates and osteonecrosis of the jaws].
    Urade M
    Clin Calcium; 2007 Feb; 17(2):241-8. PubMed ID: 17272882
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphanates.
    Pavkovic M; Petrushevska G; Jovanovic R; Karanfilski O; Cevreska L; Stankovic S; Stojanovic A
    Prilozi; 2010; 31(2):39-49. PubMed ID: 21258276
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Osteonecrosis of the Jaws (ONJ) after Bisphosphonate Treatment in Patients with Multiple Myeloma: Decreasing ONJ Incidence after Adoption of Preventive Measures.
    Catania G; Monaco F; Limberti G; Alessio M; De Martino I; Barile C; Fasciolo A; Baraldi A; Ladetto M; Fusco V
    Dent J (Basel); 2016 Dec; 4(4):. PubMed ID: 29563487
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Osteonecrosis of the maxilla and mandible in patients with advanced cancer treated with bisphosphonate therapy.
    Estilo CL; Van Poznak CH; Wiliams T; Bohle GC; Lwin PT; Zhou Q; Riedel ER; Carlson DL; Schoder H; Farooki A; Fornier M; Halpern JL; Tunick SJ; Huryn JM
    Oncologist; 2008 Aug; 13(8):911-20. PubMed ID: 18695259
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Radiologic bone loss in patients with bisphosphonate-associated osteonecrosis of the jaws: a case-control study.
    Walter C; Laux C; Sagheb K
    Clin Oral Investig; 2014; 18(2):385-90. PubMed ID: 23525860
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Large National Cohort Study of the Association between Bisphosphonates and Osteonecrosis of the Jaw in Patients with Osteoporosis: A Nested Case-control Study.
    Kwon JW; Park EJ; Jung SY; Sohn HS; Ryu H; Suh HS
    J Dent Res; 2015 Sep; 94(9 Suppl):212S-9S. PubMed ID: 26001708
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan.
    Ripamonti CI; Maniezzo M; Campa T; Fagnoni E; Brunelli C; Saibene G; Bareggi C; Ascani L; Cislaghi E
    Ann Oncol; 2009 Jan; 20(1):137-45. PubMed ID: 18647964
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Incidence of osteonecrosis of the jaw among users of bisphosphonates with selected cancers or osteoporosis.
    Tennis P; Rothman KJ; Bohn RL; Tan H; Zavras A; Laskarides C; Calingaert B; Anthony MS
    Pharmacoepidemiol Drug Saf; 2012 Aug; 21(8):810-7. PubMed ID: 22711458
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Bisphosphonate-associated osteonecrosis of the jaw].
    Krauth MT; Fügl A; Gruber R
    Wien Klin Wochenschr; 2008; 120(15-16):467-76. PubMed ID: 18820850
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Influence of prostate cancer status on the prevalence of medication-related osteonecrosis of the jaw.
    Yasui T; Kimura M; Nagamine H; Yajima S; Karube T; Sato H; Asoda S; Hara S; Onizawa K
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2021 Mar; 131(3):312-318. PubMed ID: 33431343
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bisphosphonate-associated osteonecrosis of the jaw in Ontario: a survey of oral and maxillofacial surgeons.
    Khan AA; Rios LP; Sándor GK; Khan N; Peters E; Rahman MO; Clokie CM; Dore E; Dubois S
    J Rheumatol; 2011 Jul; 38(7):1396-402. PubMed ID: 21498483
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of microcracks in the pathogenesis of bisphosphonate-related osteonecrosis of the jaw.
    Kim JW; Landayan ME; Lee JY; Tatad JC; Kim SJ; Kim MR; Cha IH
    Clin Oral Investig; 2016 Nov; 20(8):2251-2258. PubMed ID: 26795624
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epidemiology and risk factors for osteonecrosis of the jaw in cancer patients.
    Hoff AO; Toth B; Hu M; Hortobagyi GN; Gagel RF
    Ann N Y Acad Sci; 2011 Feb; 1218():47-54. PubMed ID: 20946574
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.